Advertisement

Radiation Therapy for the Treatment of Diffuse Low-Grade Gliomas

  • Stephanie E. CombsEmail author
Chapter

Abstract

The radiotherapeutic treatment of low-grade gliomas (LGG) has been a matter of discussion for centuries. Several studies have focused on the adequate dose, timing of radiation, or on combination treatments. Target volume definition is essential for high-end radiation therapy and requires strong interaction with imaging disciplines. Follow-up should be regular, including clinical assessment, imaging, and neurocognitive assessment.

Keywords

Highly conformal radiotherapy Proton radiotherapy Neurocognitive functioning Target volume definition 

References

  1. 1.
    Mirimanoff RO, Gorlia T, Mason W, van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24:2563–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.PubMedCrossRefGoogle Scholar
  3. 3.
    Combs SE, Wagner J, Bischof M, Welzel T, Edler L, Rausch R, et al. Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int J Radiat Oncol Biol Phys. 2008;71:999–1005.PubMedCrossRefGoogle Scholar
  4. 4.
    Combs SE, Wagner J, Bischof M, Welzel T, Wagner F, Debus J, et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys. 2008;70:987–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Combs SE, Gutwein S, Schulz-Ertner D, van Kampen M, Thilmann C, Edler L, et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol. 2005;181:372–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, de Witte O, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002;52:316–24.PubMedCrossRefGoogle Scholar
  7. 7.
    van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Brown PD, Jensen AW, Felten SJ, Ballman KV, Schaefer PL, Jaeckle KA, et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol. 2006;24:5427–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076–84.PubMedCrossRefGoogle Scholar
  10. 10.
    Shaw EG, Daumas-Duport C, Scheithauer BW, Gilbertson DT, O’Fallon JR, Earle JD, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg. 1989;70:853–61.PubMedCrossRefGoogle Scholar
  11. 11.
    Macdonald DR. Low-grade gliomas, mixed gliomas, and oligodendrogliomas. Semin Oncol. 1994;21:236–48.PubMedGoogle Scholar
  12. 12.
    Philippon JH, Clemenceau SH, Fauchon FH, Foncin JF. Supratentorial low-grade astrocytomas in adults. Neurosurgery. 1993;32:554–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5:1725–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Rutten E, Kazam I, Sloof JL, et al. Post-operative radiation therapy in the management of brain astrocytomas: Retrospective study of 142 patients. Int J Radiat Oncol Biol Phys. 1981;7:191–5. Ref Type: Abstract.PubMedCrossRefGoogle Scholar
  15. 15.
    Laws Jr ER, Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg. 1984;61:665–73. Ref Type: Abstract.PubMedCrossRefGoogle Scholar
  16. 16.
    Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al. A randomized trial on dose–response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549–56.PubMedCrossRefGoogle Scholar
  17. 17.
    Eyre HJ, Crowley JJ, Townsend JJ, Eltringham JR, Morantz RA, Schulman SF, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg. 1993;78:909–14.PubMedCrossRefGoogle Scholar
  18. 18.
    Eyre HJ, Quagliana JM, Eltringham JR, Frank J, O’Bryan RM, McDonald B, et al. Randomized comparisons of radiotherapy and CCNU versus radiotherapy. CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report. J Neurooncol. 1983;1:171–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer. 2005;103:802–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Buckner JC, Gesme Jr D, O’Fallon JR, Hammack JE, Stafford S, Brown PD, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003;21:251–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Shaw EG, Berkey BA, Coons SW, et al. Initial report of Radiation Therapy Oncology Group (RTOG) 90–05: prospective study in adult low-grade glioma (LGG). Proc Am Soc Clin Oncol. 2006;24:1500. Ref Type: Abstract.Google Scholar
  22. 22.
    Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30(25):3065–70. doi: 10.1200/JCO.2011.35.8598. Epub 2012 Jul 30.Google Scholar
  23. 23.
    van den Bent MJ, Chinot O, Boogerd W, Bravo MJ, Taphoorn MJ, Kros JM, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol. 2003;14:599–602.PubMedCrossRefGoogle Scholar
  24. 24.
    Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003;21:646–51.PubMedCrossRefGoogle Scholar
  25. 25.
    Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22:3133–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14:1715–21.PubMedCrossRefGoogle Scholar
  27. 27.
    Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, et al. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol. 2008;89:179–85.PubMedCrossRefGoogle Scholar
  28. 28.
    Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J. Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery. Strahlenther Onkol. 2004;180:590–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Combs SE, Welzel T, Schulz-Ertner D, Huber PE, Debus J. Differences in clinical results after LINAC-based single-dose radiosurgery versus fractionated stereotactic radiotherapy for patients with vestibular schwannomas. Int J Radiat Oncol Biol Phys. 2010;76:193–200.PubMedCrossRefGoogle Scholar
  30. 30.
    Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J. Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. Int J Radiat Oncol Biol Phys. 2005;62:797–802.PubMedCrossRefGoogle Scholar
  31. 31.
    Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23:8863–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Combs SE, Gutwein S, Thilmann C, Huber P, Debus J, Schulz-Ertner D. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol. 2005;74:167–71.PubMedCrossRefGoogle Scholar
  33. 33.
    Combs SE, Ahmadi R, Schulz-Ertner D, Thilmann C, Debus J. Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. J Neurooncol. 2005;71:319–23.PubMedCrossRefGoogle Scholar
  34. 34.
    Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05. Int J Radiat Oncol Biol Phys. 2000;47:291–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Shaw E, Scott C, Souhami L, Dinapoli R, Bahary JP, Kline R, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90–05). Int J Radiat Oncol Biol Phys. 1996;34:647–54.PubMedCrossRefGoogle Scholar
  36. 36.
    Menke M, Hirschfeld F, Mack T, Pastyr O, Sturm V, Schlegel W. Photogrammetric accuracy measurements of head holder systems used for fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1994;29:1147–55.PubMedCrossRefGoogle Scholar
  37. 37.
    Bova FJ, Buatti JM, Friedman WA, Mendenhall WM, Yang CC, Liu C. The University of Florida frameless high-precision stereotactic radiotherapy system. Int J Radiat Oncol Biol Phys. 1997;38:875–82.PubMedCrossRefGoogle Scholar
  38. 38.
    Yeung D, Palta J, Fontanesi J, Kun L. Systematic analysis of errors in target localization and treatment delivery in stereotactic radiosurgery (SRS). Int J Radiat Oncol Biol Phys. 1994;28:493–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Plathow C, Schulz-Ertner D, Thilman C, Zuna I, Lichy M, Weber MA, et al. Fractionated stereotactic radiotherapy in low-grade astrocytomas: long-term outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 2003;57:996–1003.PubMedCrossRefGoogle Scholar
  40. 40.
    Marsh JC, Godbole R, Diaz AZ, Gielda BT, Turian JV. Sparing of the hippocampus, limbic circuit and neural stem cell compartment during partial brain radiotherapy for glioma: a dosimetric feasibility study. J Med Imaging Radiat Oncol. 2011;55:442–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Marsh JC, Godbole RH, Herskovic AM, Gielda BT, Turian JV. Sparing of the neural stem cell compartment during whole-brain radiation therapy: a dosimetric study using helical tomotherapy. Int J Radiat Oncol Biol Phys. 2010;78:946–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Combs SE, Kieser M, Rieken S, Habermehl D, Jakel O, Haberer T, et al. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. BMC Cancer. 2010;10:478.PubMedCrossRefGoogle Scholar
  43. 43.
    Mizoe JE, Tsujii H, Hasegawa A, Yanagi T, Takagi R, Kamada T, et al. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:390–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Gondi V, Hermann BP, Mehta MP, Tome WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2012;83(4):e487–93.PubMedCrossRefGoogle Scholar
  45. 45.
    Gondi V, Tome WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. Radiother Oncol. 2010;97:370–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011;29(36):4776–80.PubMedCrossRefGoogle Scholar
  47. 47.
    Bauman GS, Sneed PK, Wara WM, Stalpers LJ, Chang SM, McDermott MW, et al. Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys. 1996;36:433–41.PubMedCrossRefGoogle Scholar
  48. 48.
    Combs SE, Burkholder I, Edler L, Rieken S, Habermehl D, Jakel O, et al. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial. BMC Cancer. 2010;10:533.PubMedCrossRefGoogle Scholar
  49. 49.
    Smith MA, Freidlin B, Ries LA, Simon R. Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst. 1998;90:1269–77.PubMedCrossRefGoogle Scholar
  50. 50.
    Kaplan AM, Albright AL, Zimmerman RA, Rorke LB, Li H, Boyett JM, et al. Brainstem gliomas in children. A Children’s Cancer Group review of 119 cases. Pediatr Neurosurg. 1996;24:185–92.PubMedCrossRefGoogle Scholar
  51. 51.
    Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43:959–64.PubMedCrossRefGoogle Scholar
  52. 52.
    Epstein F, Wisoff JH. Intrinsic brainstem tumors in childhood: surgical indications. J Neurooncol. 1988;6:309–17.PubMedCrossRefGoogle Scholar
  53. 53.
    Epstein F, Constantini S. Practical decisions in the treatment of pediatric brain stem tumors. Pediatr Neurosurg. 1996;24:24–34.PubMedCrossRefGoogle Scholar
  54. 54.
    Constantini S, Epstein F. Surgical indication and technical considerations in the management of benign brain stem gliomas. J Neurooncol. 1996;28:193–205.PubMedCrossRefGoogle Scholar
  55. 55.
    Zagzag D, Miller DC, Knopp E, Farmer JP, Lee M, Biria S, et al. Primitive neuroectodermal tumors of the brainstem: investigation of seven cases. Pediatrics. 2000;106:1045–53.PubMedCrossRefGoogle Scholar
  56. 56.
    Burger PC, Yu IT, Tihan T, Friedman HS, Strother DR, Kepner JL, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol. 1998;22:1083–92.PubMedCrossRefGoogle Scholar
  57. 57.
    Freeman CR, Krischer J, Sanford RA, Cohen ME, Burger PC, Kun L, et al. Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of Pediatric Oncology Group study #8495. Cancer. 1991;68:474–81.PubMedCrossRefGoogle Scholar
  58. 58.
    Freeman CR, Krischer J, Sanford RA, Burger PC, Cohen M, Norris D. Hyperfractionated radiotherapy in brain stem tumors: results of a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys. 1988;15:311–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Shrieve DC, Wara WM, Edwards MS, Sneed PK, Prados MD, Cogen PH, et al. Hyperfractionated radiation therapy for gliomas of the brainstem in children and in adults. Int J Radiat Oncol Biol Phys. 1992;24:599–610.PubMedCrossRefGoogle Scholar
  60. 60.
    Guiney MJ, Smith JG, Hughes P, Yang C, Narayan K. Contemporary management of adult and pediatric brain stem gliomas. Int J Radiat Oncol Biol Phys. 1993;25:235–41.PubMedCrossRefGoogle Scholar
  61. 61.
    Linstadt DE, Edwards MS, Prados M, Larson DA, Wara WM. Hyperfractionated irradiation for adults with brainstem gliomas. Int J Radiat Oncol Biol Phys. 1991;20:757–60.PubMedCrossRefGoogle Scholar
  62. 62.
    Landolfi JC, Thaler HT, DeAngelis LM. Adult brainstem gliomas. Neurology. 1998;51:1136–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Guillamo JS, Monjour A, Taillandier L, Devaux B, Varlet P, Haie-Meder C, et al. Brainstem gliomas in adults: prognostic factors and classification. Brain. 2001;124:2528–39.PubMedCrossRefGoogle Scholar
  64. 64.
    Combs SE, Steck I, Schulz-Ertner D, Welzel T, Kulozik AE, Behnisch W, et al. Long-term outcome of high-precision radiotherapy in patients with brain stem gliomas: results from a difficult-to-treat patient population using fractionated stereotactic radiotherapy. Radiother Oncol. 2009;91:60–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Selvapandian S, Rajshekhar V, Chandy MJ. Brainstem glioma: comparative study of clinico-radiological presentation, pathology and outcome in children and adults. Acta Neurochir (Wien). 1999;141:721–6.CrossRefGoogle Scholar
  66. 66.
    Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH. Gliomatosis cerebri: improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:1137–46.PubMedCrossRefGoogle Scholar
  67. 67.
    Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, et al. Initial chemotherapy in gliomatosis cerebri. Neurology. 2004;63:270–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of Radiation OncologyUniversity Hospital of HeidelbergHeidelbergGermany

Personalised recommendations